London, Feb 11, 2026, 07:45 GMT — Premarket
- GSK said China has taken up its filing for review of the Arexvy RSV vaccine.
- There’s a new broker target bump in play, plus a dividend date coming up later in the month—both getting traders’ attention.
GSK plc GSK.L was on investor watch in pre-market London trade Wednesday following news of new regulatory movement for its RSV vaccine in China. The shares wrapped up Tuesday’s session at 2,168 pence, a 0.42% gain.
With China representing a major untapped market for RSV vaccines, GSK is pushing to introduce Arexvy to the country’s older population. The company announced that its application to the Center for Drug Evaluation (CDE) is now under review for use against lower respiratory tract disease from RSV in adults 60 and above—a process that could stretch to 2027 before a verdict lands. Each year, GSK estimates more than six million Chinese adults in this demographic are affected by RSV, resulting in upwards of 350,000 hospitalisations tied to the virus. Arexvy has already secured approval for older adults in over 65 countries.
Investors are now probing GSK’s ability to steady its vaccines division, even as the drugmaker shifts focus toward fresh treatments to cushion the blow from upcoming patent expiries. “Accelerate what we have and to add to it via smart business development,” new CEO Luke Miels said in a Feb. 4 interview with Reuters. Reuters
Broker moves are in the mix, too. On Monday, JPMorgan bumped its GSK target up to £22.50 but stuck with a neutral rating, citing a pickup in investor sentiment and R&D momentum after last week’s numbers.
Non-executive director Hal Barron moved roughly 67,602 notional American depositary shares (ADSs) on Feb. 5, selling them at $59.17 each, a U.S. securities filing shows. The transaction, linked to a reallocation inside a company savings plan, involved the U.S.-traded ADS line.
Arexvy is up against Pfizer’s Abrysvo in the RSV space across major Western markets. Approval in China would tap into a massive, rapidly aging demographic—and could ramp up pricing pressure on vaccine makers.
Getting accepted for review is just the first hurdle—it’s hardly a stamp of approval. If the process drags out, pricing gets squeezed, or competitors make quicker moves, the commercial gains investors are eyeing now could easily shrink.
Cash returns land sooner. GSK’s ordinary shares will go ex-dividend on Feb. 19, with its ADSs following on Feb. 20 — after those dates, new buyers miss out on the next payout. The dividend is scheduled for payment on April 9.
Looking ahead, GSK’s first-quarter earnings are up next—results drop April 29. Investors will be watching for signals on vaccine demand and updates on the rollout of new products.
